Global pharma major Lupin has announced that the API manufacturing facility of its wholly-owned subsidiary, Lupin Manufacturing Solutions (LMS), in Dabhasa, Gujarat, has received the Good Manufacturing Practice (GMP) certification from the Therapeutic Goods Administration (TGA), Australia’s medicines and medical devices regulator. LMS offers pharmaceutical CDMO services and is engaged in the manufacturing and supply of APIs.

Commenting on the development, Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions said, “We are pleased to have received the GMP certification from TGA for our Dabhasa facility. As we continue to expand our global footprint, we remain focused on quality, compliance, and the highest standards of operational integrity, setting new benchmarks in the CDMO space.”

Lupin specialises in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company enjoys a strong position in India and the US across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. It has 15 state-of-the-art manufacturing sites and 7 research centres globally.